The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. Food and Drug Administration has approved three vaccines for RSV — GSK's Arexvy, Moderna's mRESVIA and Pfizer's ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...